Impilo has completed the acquisition of tandlæ – Denmark’s leading dental chain

Impilo has acquired the majority of tandlæ and will be supporting the dental chain on its continued growth journey. As part of the acquisition, the clinic leaders and the management team have reinvested significant amount of proceeds and entered into a partnership with Impilo.

In 2016, a group of investors founded tandlæ with the ambition to become Denmark’s most professional dental chain, offering high quality treatments using the latest equipment and technologies. The partnership with Impilo will provide tandlæ the opportunity to further strengthen its position as the preferred dental chain in Denmark by investing further in growth, quality and service to deliver dental care at the highest possible professional level for the benefit of patients’ dental health as well as for the continued development of its employees.

To further enable the company to realize its ambitions, several tenured healthcare services executives will support the company through the Board of Directors, including Mikael Worning as chairman of the board. Mikael comes with a long career from William Demant, which included active involvement in numerous owned and affiliated audiology clinics. Further, Mikael has relevant board experience from a number of health care companies, including The Fertility Partnership and 3Shape.

Henrik Kølle, CEO of tandlæ says: “Focus on dental health is a very important element of healthcare in Denmark. We are working on creating a strong treatment provider using high quality digital equipment and modern treatment methods, as well as on being an attractive workplace for the dentists. The partnership with Impilo is an important step enabling the chain to keep working on its ambitions. The dental industry is currently undergoing a major transformation with great opportunities offered by digitalization, and at the same time the industry is also witnessing a major generational change among the dentists. Therefore, the timing for the new owner to join the team is just right, it will be of great benefit to both employees and patients”.

Nicholas Hooge, Partner at Impilo and head of its Danish operations, says: “As a long-term and dedicated investor in the healthcare field, we at Impilo are proud to announce this partnership with the dentists and the management team of tandlæ We see a great structural need in the Danish market for a professional and well-run dental chain focusing on dental health and quality. Impilo has been following tandlæ for several years and is looking forward to supporting and strengthening the chain with additional capital and competences on its journey to be the preferred dental chain in Denmark.”


Tandlæ today supports 52 dental clinics located all across Denmark with more than 200 dentists and 800 employees.

Impilo is an investment company focused on investments in Nordic healthcare companies operating in pharmaceuticals, medical technology, healthcare services, digital health and other health-related industries. Impilo’s philosophy is that the portfolio companies must contribute to a positive development within their fields and thus overall society in order to be successful in the long-term and enable people to live healthier lives. Impilo was founded in 2017 and is currently managing approx. 1 billion EUR in capital from leading Nordic and international investors. Since its inception Impilo has been the most active investment company in the Nordic healthcare area, where tandlæ will be its 10th platform investment. Impilo’s other Danish investments include Ferrosan Medical Devices and Scantox. The company has offices in Copenhagen and Stockholm. Learn more about Impilo at


For further information please contact:

Lyngby, January 2022


KKR and Impilo announce strategic partnership together with management in rare disease platform Immedica Pharma

Stockholm and London, 23 April 2024 – Investment funds managed by KKR, a leading global investment firm, have agreed to acquire Immedica Pharma, a pharmaceutical company headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Existing owner, Nordic healthcare investment firm Impilo, will reinvest to become an equal owner alongside KKR. The transaction is subject to customary regulatory and closing conditions.

Read article

Impilo invests in Avia Pharma – a leading OTC and Rx pharmaceutical platform

Impilo has closed its investment in Avia Pharma Holding AB, a Sweden-based OTC and Rx pharmaceutical company with presence in the Nordics and Germany. Impilo now partners with two of the co-founders and management of Avia. Our ambition is to build a leading Northern European OTC / Rx platform through organic and inorganic growth.

Read article

Loargys® (pegzilarginase) approved in the EU for treatment of arginase 1 deficiency (ARG1-D)

Immedica today announces that the European Commission has granted marketing authorization of Loargys® (pegzilarginase) for the treatment of arginase 1 deficiency (ARG1-D), also known as hyperargininemia, in adults, adolescents and children aged 2 years and older. The approval follows the positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use on October 12.

Read article